Optimization of high-dose therapy for the treatment of patients with metastatic breast cancer

Journal of Oncology Pharmacy Practice

Volumn 2, Issue 1 SUPPL., 1996, Pages 11-17

  Fields, Karen K ^a   Partyka, James S ^a   Perkins, Janelle B ^a   Elfenbein, Gerald J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002169450     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155296002001s03     Document Type: Article

References (17)

1. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
2. Hryniuk W., Levine MN Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162-1170.
3. Green M. Dose-intensive chemotherapy with cytokine support. Semin Oncol. 1994;21(suppl 1):1-6.
4. Habeshaw T., Jones Jpr, Stallard S.,et al.Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol. 1991;9:295-304.
5. Marschner N., Kreienberg R., Souchon U.,et al.Evaluation of the importance and relevance of dose intensity using epirubicin an cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Semin Oncol. 1994; 21 (suppl 1):10-16.
6. Wood WC, Budman DR, Korzun AN,et al.Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast cancer. N Engl J Med. 1994; 330:1253-1259.
7. Tannock IF, Boyd NF, Deboer G.,et al.A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988; 6:1377-1387.
8. Budman DR, Wood W., Henderson IC,et al.Initial finding of CALGB 8541: A dose and dose-intensity trial of cyclophosphamide, doxorubicin and 5-fluorouracil as adjuvant treatment of stage II, node positive female breast cancer. Proc Am Soc Clin Oncol. 1992;11:A29.
9. Dimitrov N., Anderson S., Fisher B.,et al.Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22. Proc Am Soc Clin Oncol. 1994;13:A58.
10. Fields KK, Elfenbein GJ, Lazarus HM,et al.Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile. J Clin Oncol. 1995;12:323-332.
11. Fields KK, Elfenbein GJ, Perkins JB,et al.Two novel high dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Semin Oncol. 1993;20(suppl 6):59-66.
12. Fields KK, Perkins JB, Elfenbein GJ,et al.A phase I dose escalation trial of high dose taxol, novantrone, and thiotepa (TNT) followed by autologous stem cell rescue: Toxicity. Proc Amer Soc Clin Oncol. 1995;14:953.
13. Fields KK, Zorsky PE, Hiemenz JW,et al.Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity. J Clin Oncol. 1994; 12:544-552.
14. Fields KK, Elfenbein GJ, Perkins JB,et al.Event-free survival in breast cancer patients treated with high dose ifosfamide, carboplatin, and etoposide and autologous stem cell rescue: analysis of risk factors. In: Einhorn J, Nord C, and Norrby S, eds. Recent advances in Chemotherapy, Proceedings of the 18th International Congress of Chemotherapy. Washington DC: 1994;974-975.
15. Fields KK, Perkins JB, Elfenbein GJ Reply to Letter-to-the-Editor. J Clin Onc. 1995;13:1826-1827.
16. Perkins JB, Fields KK, Elfenbein GJ Ifosfamide, carboplatin, and etoposide (ICE) chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation (AHSCT): Evaluation of dose response relationships. Semin Oncol. 1995;22(suppl 7):5- 8.
17. Perkins JP, Elfenbein GJ, Fields KK Analysis of dose response relationships in the setting of high dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: Implications for the treatment of patients with advanced breast cancer. Semin Oncol. 1996;(in press).